Anzeige
Mehr »
Login
Mittwoch, 22.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Mit dieser Aktie könntest Du von der Cannabis-Legalisierungswelle profitieren!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EFRZ | ISIN: US09077D2099 | Ticker-Symbol: AI10
München
22.05.24
08:01 Uhr
1,020 Euro
0,000
0,00 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
BIOFRONTERA INC Chart 1 Jahr
5-Tage-Chart
BIOFRONTERA INC 5-Tage-Chart

Aktuelle News zur BIOFRONTERA INC Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
15.05.Biofrontera Inc. - 8-K, Current Report4
15.05.Biofrontera Inc. Reports First Quarter 2024 Financial Results and Provides a Business Update337Conference call begins at 10:00 a.m. Eastern time on Thursday, May 16, 2024 WOBURN, MA / ACCESSWIRE / May 15, 2024 / Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing...
► Artikel lesen
10.05.NOTV, BFRI and CPOP among pre-market losers7
06.05.Biofrontera Inc. to Report First Quarter 2024 Financial Results on May 15, 2024269WOBURN, MA / ACCESSWIRE / May 6, 2024 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that it will report...
► Artikel lesen
03.05.Biofrontera Inc. - 8-K, Current Report2
03.05.Biofrontera Inc.: Biofrontera Announces Achievement of Two Milestones Associated with Series B-3 Convertible Preferred Stock Warrants241WOBURN, MA / ACCESSWIRE / May 3, 2024 / Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced...
► Artikel lesen
03.05.Biofrontera Inc. - S-1, General form for registration of securities1
25.04.Biofrontera Inc. - 8-K, Current Report3
26.03.Biofrontera Inc. - 8-K, Current Report6
26.03.Biofrontera Inc. Announces 2024 Annual Meeting of Stockholders and Deadlines for Submission of Stockholder Proposals404WOBURN, MA / ACCESSWIRE / March 26, 2024 / Biofrontera, Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced...
► Artikel lesen
20.03.Biofrontera Inc. - S-1/A, General form for registration of securities2
19.03.Biofrontera Inc. (BFRI) Q4 2023 Earnings Call Transcript4
16.03.Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update1.237Conference call begins at 10:00 a.m. Eastern time on Monday, March 18, 2024WOBURN, MA / ACCESSWIRE / March 15, 2024 / Biofrontera, Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing...
► Artikel lesen
16.03.Biofrontera Inc reports results for the quarter ended in December - Earnings Summary5
15.03.Biofrontera Inc. - 8-K, Current Report7
15.03.Biofrontera Inc. - 10-K, Annual Report5
08.03.Biofrontera Inc. to Report Fourth Quarter and Full Year 2023 Financial Results on March 15, 2024289WOBURN, MA / ACCESSWIRE / March 8, 2024 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that it will report...
► Artikel lesen
23.02.Biofrontera Inc. Announces Closing of Private Placement of up to $16.0 Million Priced at Market per Nasdaq Rules522Company closed financing of $8.0 million with an additional $8.0 million second tranche tied to milestones for aggregate proceeds of $16 million gross priced at market per Nasdaq rulesFunding and recent...
► Artikel lesen
20.02.Biofrontera Inc. - 8-K, Current Report4
20.02.Biofrontera Inc. Announces Private Placement of Up To $16.0 Million Priced at Market per Nasdaq Rules316Company secures financing of $8.0 million with an additional $8.0 million second tranche tied to milestones for aggregate proceeds of $16 million gross priced at market per Nasdaq rulesFunding and recent...
► Artikel lesen
Seite:  Weiter >>
59 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1